An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...